A belated but grateful update to wrap up 2024, reflecting our progress and appreciation for your continued support.
Pilatus Biosciences
Biotechnologieforschung
Épalinges, Switzerland 416 Follower:innen
Harnessing Immunometabolism for Cancer Therapy
Info
Shaping the Future of Cancer Treatment through Trailblazing First-in-class Biologics focusing on Metabolic Checkpoints, propelling revolutionary immune-microenvironment reprogramming to conquer cancer's greatest challenges.
- Website
-
https://www.pilatusbio.com
Externer Link zu Pilatus Biosciences
- Branche
- Biotechnologieforschung
- Größe
- 11–50 Beschäftigte
- Hauptsitz
- Épalinges, Switzerland
- Art
- Privatunternehmen
- Gegründet
- 2022
Orte
-
Primär
Wegbeschreibung
Route de la Corniche 6, 1066, Épalinges, Switzerland.
Épalinges, Switzerland 1066, CH
Beschäftigte von Pilatus Biosciences
-
Ho Ping-Chih
Full member at Ludwig Cancer Research
-
Yi-Ru Yu
Biological Research Scientist | Cancer Immunology | Immunotherapy | Pre-clinical Pharmacology | Translational Medicine
-
Laura Fernandez
Researcher in Immunometabolism
-
LUTING CHIU
Bioinformatics | AI & Machine learning| Data Scientist | Cancer Research | Immunotherapy
Updates
-
We are thrilled to share that Pilatus Biosciences Inc. has reached a significant milestone. The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its leading molecule, PLT012, for the treatment of liver and intrahepatic bile duct cancer (HCC/ICCA). This achievement, realized in November 2024, marks a pivotal step forward in developing innovative therapies for patients facing these formidable challenges. Congratulations to the entire Pilatus Biosciences team for their dedication and hard work! #CancerResearch #BiotechInnovations #TeamInnovation #ScienceForLife
More to come...
Pilatus Biosciences Inc. Receives Orphan Drug Designation from FDA for PLT012 in Treatment of Liver and Intrahepatic Bile Duct Cancer
Raven Lin auf LinkedIn
-
Exciting news from our team! Join us at the Festival of Biologics on October 16 in Basel, where our R&D Senior Scientist, Yi-Ru Yu, will be presenting groundbreaking research. Discover how the first-in-class antibody, PLT012, is revolutionizing cancer treatment by targeting CD36 and unleashing anti-tumor immunity through metabolic reprogramming in the tumor microenvironment. Don't miss it! #FestivalOfBiologics #CancerResearch #BiotechInnovations #TeamInnovation #ScienceForLife https://lnkd.in/emZ2Pu9m
Festival of Biologics | LinkedIn
linkedin.com
-
🚀 Pilatus Biosciences achievements published in the TTA Magazine! 🚀 We are thrilled to share that Pilatus Biosciences is featured in the latest issue of Taiwan Tech Arena Magazine (#15) from September 2024! This recognition highlights our groundbreaking work in the field of immunotherapy. Enjoy your reading!
-
The Pilatus Biosciences team will attend #ASCO24 in Chicago. Let's get together and share expertise! 💡🌟🔬
It's not too late to join us at the most significant gathering of oncology professionals worldwide. Register for #ASCO24 today! https://brnw.ch/21wK8if
-
🌟Exciting news! 🌟 We are very proud of our CEO, Raven Lin, who is taking part in the panel session of the 10th Annual Oncology Innovation Forum in Chicago on May 31st, 2024! Don't miss! 🚀✨
🎯🔬 Redefining Success in Oncology: New Endpoints for Early-Stage Companies. Join us at the 'New Endpoints for Early-Stage Oncology Companies Panel' during the #Sachs_OIF on May 31st, 2024, at the Waldorf Astoria Chicago Hotel. Discover the evolving metrics that are setting new standards for early-stage oncology research and development. Chaired by: Jeff Bockman, EVP Expert Advisor, Oncology, Lumanity Head, Oncology Center of Excellence, Lumanity Panellists: Colette Lipp, Director, Global BD Oncology & Immuno-Oncology, Merck KGaA, Darmstadt, Germany Jim Barlow, President & CEO, ImmunoGenesis, Inc. Matthew Price, Co-Founder, EVP & Chief Operating Officer, Promontory Therapeutics Inc. Nadim Ahmed, President & CEO, Cullinan Therapeutics, Inc. Raven Lin, Co-Founder & CEO, Pilatus Biosciences SA Don't miss this opportunity to gain invaluable insights and network with the forefront of oncology innovation. Register now at https://lnkd.in/eGr3AbXN and be part of the conversation that's shaping the next generation of oncology success stories, both #inperson & #online. #OncologyEndpoints #EarlyStageOncology #CancerResearch #BiotechInnovation #Pharma #SachsForum #ASCO2024
-
-
We are #hiring a R&D scientist in Epalinges, Vaud. Apply today or share this post with your network.
-
See you in Washington DC!!! I will present our new work on immunometabolism and tumor microenvironment.
Registration is now open for the Eighth International Cancer Immunotherapy Conference: Translating Science into Survival! Presented by the Cancer Research Institute and the European Network for Cancer Immunotherapy, CICON continues to be the most important forum for basic and translational research in cancer immunology and immunotherapy. #CICON24 will include nine sessions, featuring more than 30 plenary lectures, and 20+ proffered talks selected from among the submitted abstracts. These exciting sessions will cover the future of the field of cancer immunology, including neoadjuvant and platform trials, multiomic data analysis, tertiary lymphoid aggregates as regulators of anti-cancer immunity, immune health and inflammation, metabolism, the microbiome, personalized therapies, and much more. Register now: https://bit.ly/42E4K3v #CICON #Immunotherapy #CancerResearch
-